Trial Profile
Pharmacodynamics of BIBF1120 (Nintedanib) on fibulin-1 protein in subjects with idiopathic pulmonary fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2016
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacodynamics
- 19 Jan 2016 New trial record